Pharmacovigilance Evaluation Of Refacto In Usual Care Settings
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration
Patients with hemophilia A
Drug: Moroctocog alfa
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Name: ReFacto
Patients with Hemophilia A
Intervention: Drug: Moroctocog alfa
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Actual Enrollment (submitted: December 22, 2010)
Original Enrollment (submitted: September 13, 2005)
Actual Study Completion Date
Actual Primary Completion Date
January 2010 (Final data collection date for primary outcome measure)
Proven diagnosis of Hemophilia A
Contraindications according to Summary of Product Characteristics
Sexes Eligible for Study:
Child, Adult, Older Adult
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects